Histone deacetylase inhibitors (HDACis) are one of the last frontiers in pharmaceutical
research. Several classes of HDACi have been identified. Although more than 20 HDACi are …

Nephrotoxicity is one of the important dose-limiting factors during cisplatin treatment. There
is a growing body of evidence that activation of p53 has a critical role in cisplatin-induced …

Histone deacetylases (HDACs) are enzymes that balance the acetylation activities of histone
acetyltransferases on chromatin remodeling and play essential roles in regulating gene …

The molecular mechanisms of aging are the subject of much research and have facilitated
potential interventions to delay aging and aging-related degenerative diseases in humans …

Colorectal cancer is still a major health problem worldwide. Based on the most recent
released data by the World Health Organization GLOBOCAN in 2012, colorectal cancer is …

Histone deacetylases (HDACs) mediate histone deacetylation and act in concert with
histone acetyltransferases to regulate dynamic and reversible histone acetylation which …

Epigenetic modifications determine phenotypic characteristics in a reversible, stable and
genotype-independent manner. Epigenetic modifications mainly encompass CpG island …

Cholangiocarcinoma (CCA) is an aggressive biliary tract malignancy with limited treatment
options and low survival rates. Currently, there are no curative medical therapies for CCA …

Cancer is a complex pathology that causes a large number of deaths worldwide. Several
risk factors are involved in tumor transformation, including epigenetic factors. These factors …

Clinical and experimental studies show that inhibition of histone/protein deacetylases
(HDAC) can have important anti-neoplastic effects through cytotoxic and proapoptotic …